Front Mol Biosci:寻常型银屑病的个性化干预:用代谢组学方法对患者进行分子分型

2022-08-17 医路坦克 MedSci原创

寻常型银屑病(PV)是一种复杂的自身免疫性疾病,我们利用血清代谢组学对PV根据脂代谢改变进行亚型的分子证据进行了探索,并验证这种亚型是否可能有助于个性化治疗的发展。

寻常型银屑病(PV)是一种复杂的自身免疫性疾病,以皮肤红斑为特征,缺乏有效的治疗方法。PV与代谢综合征和心血管疾病的风险增加有关,这两者都是由全身炎症和异常代谢之间的相互作用所介导的。然而,不同严重程度的PV在脂代谢方面是否存在差异仍不清楚。因此,我们利用血清代谢组学对PV根据脂代谢改变进行亚型的分子证据进行了探索,并验证这种亚型是否可能有助于个性化治疗的发展。

从2019年1月至2019年11月,皮肤科诊所招募了PV患者,并根据是否存在代谢合并症及其银屑病面积和严重程度指数(PASI)对患者进行了分类。我们对血清样本进行了有针对性的代谢组学分析,并确定了代谢物成分与PASI评分之间的相关性。

本研究共123名受试者,88名PV患者和35名健康受试者。将PV患者分为“PVM组”(合并代谢合并症的PV)和“PV组”(无代谢合并症的PV),并进一步分为“轻度PV”(MP,PASI<10)和“重度PV”(SP,PASI≥10)组。与匹配的健康对照组相比,MP亚组的27种代谢物和SP亚组的28种代谢物的水平发生了变化。在MP亚组中,SM(D16:0/17:1)和SM(D19:1/20:0)与PASI呈正相关,而在SP亚组中,Cer(D18:1/18:0)、PC(18:0/22:4)和PC(20:0/22:4)与PASI呈正相关。PVM组17种代谢物水平明显高于PV组,尤其是神经酰胺和磷脂酰胆碱。相关分析表明,Cer(D18:1/18:0)和SM(D16:1/16:1)不仅与PASI相关,而且与生化指标呈显著正相关。

火山图说明了不同的代谢物。(A)MP和HC-MP亚组之间差异代谢物的火山图。(B)SP和HC-SP亚组之间差异代谢物的火山图。(C)MP和SP亚组之间差异代谢物的火山图。(D)PVM组和PV组之间的差异代谢物的火山图。HC-MP,寻常型银屑病轻度组;HC-SP,寻常型银屑病重度组;MP,寻常型银屑病轻度组;SP,重度寻常型银屑病;PV,寻常型银屑病无代谢性疾病组;PVM,寻常型银屑病伴代谢性疾病组。

热图显示了斯皮尔曼改变的代谢物之间的相互关系。(A)MP亚组中改变的代谢物(MP与HC-MP)的相关热图。(B)SP亚组中改变的代谢物(SP与HC-SP)的相关热图。(C)MP亚组中改变代谢物(MP与SP)的相关热图。(D)SP亚组中改变的代谢物(MP与SP)的相关热图。(E)PVM组中改变的代谢物(PVM与PV)的相关热图。用Spearman相关系数进行相关分析,*p<0.001,**p<0.01,*p<0.001。HC-MP,寻常型银屑病轻度组;HC-SP,寻常型银屑病重度组;MP,寻常型银屑病轻度组;SP,重度寻常型银屑病;PV,寻常型银屑病无代谢性疾病组;PVM,寻常型银屑病伴代谢性疾病组。

Spearman的代谢物改变与PASI的相关性。(A)PASI与MP亚组改变代谢产物(MP与HC-MP)的相关分析:SM(D16:1/17:0):r=0.37,p=0.041;SM(D19:1/20:0):r=0.39,p=0.032。(B)PASI与改变的代谢物(SP)vs PC(18:0/22:4):r=0.45,p=0.015;PC(20:0/22:4):r=0.39,p=0.029。PASI,银屑病面积和严重程度指数;HC-MP,健康对照组与轻度寻常型银屑病组匹配;HC-SP,健康对照组与重度寻常型银屑病组匹配;MP,轻度寻常型银屑病;SP,重度寻常型银屑病组。

这项研究的结果表明,不同严重程度的PV患者具有不同的代谢特征,代谢紊乱使疾病的发展复杂化。这些发现将有助于我们了解PV的病理进展,并为PV的精确治疗制定策略。

文献来源:Dai D,  He C,  Wang S, Toward Personalized Interventions for Psoriasis Vulgaris: Molecular Subtyping of Patients by Using a Metabolomics Approach.Front Mol Biosci 2022;9

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1919482, encodeId=93e81919482f2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 16 03:09:58 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944293, encodeId=31ea1944293f5, content=<a href='/topic/show?id=24064668126' target=_blank style='color:#2F92EE;'>#寻常型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46681, encryptionId=24064668126, topicName=寻常型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Sun Jan 01 18:09:58 CST 2023, time=2023-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079611, encodeId=2e5420e961141, content=<a href='/topic/show?id=b817466e8c2' target=_blank style='color:#2F92EE;'>#寻常型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46678, encryptionId=b817466e8c2, topicName=寻常型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Aug 31 21:09:58 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480333, encodeId=4026148033310, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Tue Aug 16 15:09:58 CST 2022, time=2022-08-16, status=1, ipAttribution=)]
    2022-10-16 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1919482, encodeId=93e81919482f2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 16 03:09:58 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944293, encodeId=31ea1944293f5, content=<a href='/topic/show?id=24064668126' target=_blank style='color:#2F92EE;'>#寻常型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46681, encryptionId=24064668126, topicName=寻常型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Sun Jan 01 18:09:58 CST 2023, time=2023-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079611, encodeId=2e5420e961141, content=<a href='/topic/show?id=b817466e8c2' target=_blank style='color:#2F92EE;'>#寻常型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46678, encryptionId=b817466e8c2, topicName=寻常型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Aug 31 21:09:58 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480333, encodeId=4026148033310, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Tue Aug 16 15:09:58 CST 2022, time=2022-08-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1919482, encodeId=93e81919482f2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 16 03:09:58 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944293, encodeId=31ea1944293f5, content=<a href='/topic/show?id=24064668126' target=_blank style='color:#2F92EE;'>#寻常型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46681, encryptionId=24064668126, topicName=寻常型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Sun Jan 01 18:09:58 CST 2023, time=2023-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079611, encodeId=2e5420e961141, content=<a href='/topic/show?id=b817466e8c2' target=_blank style='color:#2F92EE;'>#寻常型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46678, encryptionId=b817466e8c2, topicName=寻常型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Aug 31 21:09:58 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480333, encodeId=4026148033310, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Tue Aug 16 15:09:58 CST 2022, time=2022-08-16, status=1, ipAttribution=)]
    2022-08-31 cenghis
  4. [GetPortalCommentsPageByObjectIdResponse(id=1919482, encodeId=93e81919482f2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 16 03:09:58 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1944293, encodeId=31ea1944293f5, content=<a href='/topic/show?id=24064668126' target=_blank style='color:#2F92EE;'>#寻常型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46681, encryptionId=24064668126, topicName=寻常型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Sun Jan 01 18:09:58 CST 2023, time=2023-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079611, encodeId=2e5420e961141, content=<a href='/topic/show?id=b817466e8c2' target=_blank style='color:#2F92EE;'>#寻常型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46678, encryptionId=b817466e8c2, topicName=寻常型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Wed Aug 31 21:09:58 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1480333, encodeId=4026148033310, content=<a href='/topic/show?id=2f6f2546977' target=_blank style='color:#2F92EE;'>#代谢组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25469, encryptionId=2f6f2546977, topicName=代谢组)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f1e7632392, createdName=ms6897892027066920, createdTime=Tue Aug 16 15:09:58 CST 2022, time=2022-08-16, status=1, ipAttribution=)]

相关资讯

中草药对高脂饮食致小鼠肥胖的影响

国际上肥胖人口不断增加,并伴随着各种代谢综合征。在传统中医和韩国医学中,九药汤 (JST) 是治疗糖尿病 (DM) 的处方。然而,很少有科学证据表明它对糖尿病的影响。

Evid Based Complement Alternat Med:如何利用代谢组学辨别中医的体质?

北京中医药大学王琦教授开发的《中医体质分类标准》和《中医体质九大体质分类量表》是目前公认的中医体质诊断标准。

先天性心脏病相关肺动脉高压患者缺损修复围手术期血浆代谢组学研究

通过缺损修复手术和个性化治疗,先天性心脏病相关肺动脉高压(CHD-PAH)患者的生活质量和生存率得到了极大改善。然而,手术后存活的患者仍可能面临持续性 PAH 的风险,预后可能比未手术的患者差得多。

Front Pharmacol:栀子豉汤通过调节GSH/GSSG途径减轻氧化应激损伤逆转CUMS大鼠抑郁行为

从细胞和动物水平验证栀子豉汤抗抑郁作用中谷胱甘肽途径的抗氧化作用。

Rheumatology:组氨酸是系统性红斑狼疮发病机制中的生物标志物

研究系统性红斑狼疮(SLE)患者血浆中代谢物的变化,以识别新的生物标志物,为SLE发病机制提供线索。

肺动脉高压所致右心室衰竭的蛋白质组学和代谢组学分析

该研究描述了MCT诱导的PAH进展过程中RV心肌的蛋白质组和代谢组概况,同时也为潜在的治疗目标提供了见解,促进了PAH中RV功能障碍的延缓或逆转。